BioOrbit

BioOrbit raised a £9.8m seed round on 30 April 2026, co-led by LocalGlobe and Breega, with participation from Auxxo, Seedcamp, Type One and 7percent. The round was the world's largest seed for in-space drug manufacturing and closed a regulatory loop that opened on 5 March 2026, when the UK Space Agency, MHRA, Regulatory Innovation Office and Civil Aviation Authority jointly published a pathway for space-manufactured drugs naming BioOrbit as the pioneering commercial case .

BioOrbit's core product is the BOX unit (BioOrbit Orbital eXperiment), roughly the size of a microwave, designed to manufacture pharmaceutical drug crystals in microgravity at commercial scale. Microgravity crystallisation can yield pharmaceutical compounds with purer crystal structures and higher efficacy than ground-based manufacturing permits, because convection currents that disrupt crystal growth in Earth's gravity are absent in orbit. The UK Space Agency had previously awarded BioOrbit a £250,000 contract under the PHARM study (Pharmaceutical Manufacturing in Microgravity) to design a regulatory-compliant in-orbit mission.

BioOrbit demonstrates a replicable pattern in British deep tech: government writing the regulatory framework, private capital following. The 5 March pathway from four agencies was a structural precondition for the £9.8m round; the international investor list (Breega is a European fund) reflects confidence in a British regulatory instrument. The contrast with CamGraPhIC, whose factory moved to Pisa and Bergamo after European Commission state-aid clearance , shows the pattern is not automatic: British regulatory scaffolding held BioOrbit onshore where EC state-aid mechanics moved CamGraPhIC offshore.